Investor presentation and restated targets

Tristel (LSE:TSTL) told the market on 9 November 2026 that it will present and exhibit at the Mello2026 investor event on 18 November, with executive sessions scheduled for 09:00 and 13:50. The notice did, however, restate the financial framework by which management asks to be judged, which makes it a useful moment to compare those targets with the results published on 19 October.

Tristel, based in Cambridgeshire, makes chlorine dioxide disinfectants used mainly to decontaminate reusable medical instruments such as ultrasound probes and endoscopes. According to the 9 November announcement it employs about 280 people across 16 subsidiaries and sells into more than 40 countries.

About the company

Tristel makes chlorine dioxide disinfectants used to clean reusable medical instruments such as ultrasound probes and endoscopes. It employs about 280 people across 16 subsidiaries and sells in more than 40 countries. Sales of the products to hospitals and clinics recur as instruments are cleaned after each use.

The stated targets

The framework restated in the notice has four elements: double-digit annual Revenue growth, an adjusted EBITDA Margin of at least 25%, profitability without debt, and a progressive Dividend policy. These are standing ambitions rather than a forecast for the current financial year, and the announcement did not attach a timetable or update guidance.

What the latest results showed

For the year to 30 June 2026, revenue rose 10% to £51.1m from £46.5m, according to the final results. That meets the growth target, though only at its lower boundary. Sales of medical device disinfectants rose 11% and were the main driver, while overseas markets accounted for 64% of revenue.

Reported pre-tax profit increased 31% to £11.0m from £8.4m, and adjusted pre-tax profit rose 15% to £11.7m. The company gave a gross margin of 82% and cash and short-term investments of £16.0m, with the group debt-free. The Dividend per share was raised 5% to 14.91p, consistent with the progressive policy.

Adjusted pre-tax profit equalled roughly 23% of revenue; EBITDA, which excludes Depreciation and amortisation, would be higher, but the precise margin should be taken from the company's own disclosure.

Why North America matters to the targets

Sustaining double-digit growth depends heavily on the United States, where the board has identified a key opportunity after the Food and Drug Administration cleared two products: Ult, for ultrasound probes, and OPH, for ophthalmic devices. The company pointed to an increased US contribution without quantifying it. The company also launched a paid premium tier of its 3T Pro digital compliance platform after the year end.

Leadership is changing. LSE:TSTL announced on 17 June 2026 that Chris Lee had been appointed chief executive, and the non-executive chair, Bruno Holthof, said the board would balance Investment with disciplined execution and cash generation.

Risks to watch

US adoption of new disinfection methods typically depends on hospital procurement cycles and on clinicians changing established practice, so the speed of revenue growth there is uncertain. Investment in American sales and regulatory work could weigh on margins before it pays back. LSE:TSTL also relies on a single core chemistry, which concentrates technical and regulatory exposure, and it competes with larger infection-prevention suppliers. Currency movements affect a Business with most of its sales overseas. The transition to a new chief executive adds execution risk while strategic priorities are set.

Comparing results with targets

Revenue growth of 10% meets the double-digit target at its lower boundary. Adjusted pre-tax profit of £11.7m on revenue of £51.1m is about 22.9%, as the company reports about 23%. The EBITDA margin target of at least 25% would require EBITDA of at least about £12.8m on that revenue. Since EBITDA adds depreciation and Amortisation to operating profit, it is likely to be above the adjusted pre-tax profit, which gives some support to that target, but the company's own disclosure should be used for the exact figure.

Profit and cash

Reported pre-tax profit of £11.0m, up 31% from £8.4m, grew faster than adjusted profit of £11.7m, up 15%, which suggests that adjusting items were smaller this year than last. A gross margin of 82% is high, typical of a product with low production costs relative to price. Cash and short-term investments of £16.0m with no Debt satisfy the target of profitability without debt. The dividend of 14.91p, up 5%, grew more slowly than profit, as the company follows a progressive policy.

Geography

Overseas markets accounted for 64% of revenue, which means the UK is about 36%. Medical device disinfectants grew 11%, ahead of the group's 10%, so they account for a rising share. Reliance on the US for the next stage of growth is noted by the board, with regulatory clearance and market access as relevant factors.

The investor event

Executive sessions are at 09:00 and 13:50 on 18 November, and the slides will be posted on the investor website. The useful comparison is between the targets and the published results.

The US opportunity and regulation

The company's growth plan relies on the United States, where hospital infection control rules set the standards for how instruments are cleaned. Gaining regulatory clearance for a disinfectant is a lengthy process, and selling into hospitals involves long evaluation periods. Once a product is adopted, it tends to be reordered because it is used with every instrument cleaning.

Overseas markets already account for 64% of revenue, so the group has experience of operating in different regulatory systems through its 16 subsidiaries. That experience helps it to enter new countries, but each market has its own approval requirements.

The presence at an investor event on 18 November is an opportunity for management to restate its framework, and the slides will be posted on the website. For investors, the useful exercise is to compare the targets with the published results, as set out above.

The four targets taken together describe a business that wants to grow its revenue by at least 10% a year while keeping a high margin and no debt. The year to June 2026 met the revenue and debt targets and, on the adjusted profit measure, was close to the margin target.

What comes next

The next substantive checkpoint is likely to be trading for the half year to 31 December 2026, where investors can test whether growth remains in double digits.